Legend Biotech has announced promising early Phase 1 data for LB2501, a novel in vivo CAR-T therapy targeting CD19/CD20, which achieved a 100% objective response rate and 83.3% complete response rate in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, without serious adverse events. This off-the-shelf approach could simplify CAR-T therapy manufacturing and improve patient access. Despite the excitement around LB2501, key risks remain, particularly concerning the commercial success of its current treatment, CARVYKTI, which has treated over 10,000 patients. Analysts have varying revenue estimates for Legend Biotech, projecting significant growth that could position the stock well above its current value.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-legn/legend-biotech/news/why-legend-biotech-legn-is-up-229-after-early-success-with-o
